Predictive value of apelin-12 in patients with ST-elevation myocardial infarction with different renal function: a

Lingchang Yang1, Ting Zheng1, Haopeng Wu1

  • 1Department of Emergency Medicine, The First People's Hospital of Taizhou, Taizhou, Zhejiang, China.

BMJ Open
|November 19, 2017
PubMed

Insights

Low levels of apelin-12 predict major adverse cardiovascular events (MACEs) in ST-segment elevation myocardial infarction (STEMI) patients post-primary percutaneous coronary intervention (pPCI). This finding is particularly relevant for patients with normal estimated glomerular filtration rate (eGFR).

Area of Science:

  • Cardiology
  • Biomarkers
  • Interventional Cardiology

Background:

  • Apelin-12 is crucial for cardiovascular homeostasis, but its prognostic significance is not well-established.
  • Understanding predictors of adverse events after ST-segment elevation myocardial infarction (STEMI) is vital for patient outcomes.

Purpose of the Study:

  • To identify factors predicting major adverse cardiovascular events (MACEs) following primary percutaneous coronary intervention (pPCI) in STEMI patients.
  • To evaluate the prognostic value of apelin-12 levels in this patient cohort.

Main Methods:

  • A cohort of 464 STEMI patients undergoing successful pPCI were followed for 2.5 years.
  • Multivariate Cox regression and ROC curve analyses were employed to determine independent predictors of MACEs.

Main Results:

  • Low apelin-12 levels were identified as an independent predictor of MACEs (HR=0.132, P<0.001).
  • Other significant predictors included low left ventricular ejection fraction, low estimated glomerular filtration rate (eGFR), Killip's classification >I, and pathological Q-wave.
  • Low apelin-12 also predicted poorer in-hospital prognosis and MACEs, especially in patients with normal eGFR.

Conclusions:

  • Lower apelin-12 levels are associated with an increased risk of MACEs in STEMI patients treated with pPCI.
  • The prognostic value of apelin-12 is particularly pronounced in patients with normal eGFR, highlighting its potential as a predictive biomarker.
Abstract

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
357
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
248
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
507
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
622